Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer

Cancer Genetics and Cytogenetics

Volumn 173, Issue 2, 2007, Pages 131-135

  Marín Aguilera, Mercedes ^a,b   Mengual, Lourdes ^a,b   Ribal, María José ^a   Burset, Moisès ^a,b   Arce, Yolanda ^b   Ars, Elisabet ^b   Oliver, Artur ^b   Villavicencio, Humberto ^b   Algaba, Ferran ^b   Alcaraz, Antonio ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b FUNDACIÓ PUIGVERT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME ABERRATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; URINALYSIS; URINE CYTOLOGY; UROTHELIUM;

AGED; CYTODIAGNOSIS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 33847142259     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.10.011     Document Type: Article

References (35)

1. Amira N., Mourah S., Rozet F., Teillac P., Fiet J., Aubin P., Cortesse A., Desgrandchamps F., Le Duc A., Cussenot O., and Soliman H. Non-invasive molecular detection of bladder cancer recurrence. Int J Cancer 101 (2002) 293-297
2. Maier U., Simak R., and Neuhold N. The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol 48 (1995) 314-317
3. Grossman H.B. New methods for detection of bladder cancer. Semin Urol Oncol 16 (1998) 17-22
4. Murphy W.M., Rivera-Ramirez I., Medina C.A., Wright N.J., and Wajsman Z. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J Urol 158 (1997) 2102-2106
5. Perez Garcia F.J., Eyo A., Escaf Barmadah S., and Fernandez Gomez J.M. [NMP-22 test. Is it useful in the follow-up of patients with superficial bladder tumor?]. In Spanish. Arch Esp Urol 55 (2002) 1201-1208
6. Ramakumar S., Bhuiyan J., Besse J.A., Roberts S.G., Wollan P.C., Blute M.L., and O'Kane D.J. Comparison of screening methods in the detection of bladder cancer. J Urol 161 (1999) 388-394
7. Mian C., Pycha A., Wiener H., Haitel A., Lodde M., and Marberger M. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 161 (1999) 1486-1489
8. Glas A.S., Roos D., Deutekom M., Zwinderman A.H., Bossuyt P.M., and Kurth K.H. Tumor markers in the diagnosis of primary bladder cancer: a systematic review. J Urol 169 (2003) 1975-1982
9. Lokeshwar V.B., and Soloway M.S. Current bladder tumor tests: does their projected utility fulfill clinical necessity?. J Urol 165 (2001) 1067-1077
10. Lotan Y., and Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61 (2003) 109-118
11. Zhao J., Richter J., Wagner U., Roth B., Schraml P., Zellweger T., Ackermann D., Schmid U., Moch H., Mihatsch M.J., Gasser T.C., and Sauter G. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res 59 (1999) 4658-4661
12. Reeder J.E., Morreale J.F., O'Connell M.J., Stadler W.M., Olopade O.F., Messing E.M., and Wheeless L.L. Loss of the CDKN2A/p16 locus detected in bladder irrigation specimens by fluorescence in situ hybridization. J Urol 158 (1997) 1717-1721
13. Pycha A., Mian C., Haitel A., Hofbauer J., Wiener H., and Marberger M. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J Urol 157 (1997) 2116-2119
14. Sauter G., Gasser T.C., Moch H., Richter J., Jiang F., Albrecht R., Novotny H., Wagner U., Bubendorf L., and Mihatsch M.J. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. Urol Res 25 Suppl 1 (1997) S37-S43
15. Richter J., Jiang F., Gorog J.P., Sartorius G., Egenter C., Gasser T.C., Moch H., Mihatsch M.J., and Sauter G. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 57 (1997) 2860-2864
16. Balazs M., Carroll P., Kerschmann R., Sauter G., and Waldman F.M. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer 19 (1997) 84-89
17. Sokolova I.A., Halling K.C., Jenkins R.B., Burkhardt H.M., Meyer R.G., Seelig S.A., and King W. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2 (2000) 116-123
18. Halling K.C., King W., Sokolova I.A., Karnes R.J., Meyer R.G., Powell E.L., Sebo T.J., Cheville J.C., Clayton A.C., Krajnik K.L., Ebert T.A., Nelson R.E., Burkhardt H.M., Ramakumar S., Stewart C.S., Pankratz V.S., Lieber M.M., Blute M.L., Zincke H., Seelig S.A., Jenkins R.B., and O'Kane D.J. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 167 (2002) 2001-2006
19. Halling K.C., King W., Sokolova I.A., Meyer R.G., Burkhardt H.M., Halling A.C., Cheville J.C., Sebo T.J., Ramakumar S., Stewart C.S., Pankratz S., O'Kane D.J., Seelig S.A., Lieber M.M., and Jenkins R.B. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164 (2000) 1768-1775
20. Varella-Garcia M., Akduman B., Sunpaweravong P., Di Maria M.V., and Crawford E.D. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol 22 (2004) 16-19
21. Bubendorf L., Grilli B., Sauter G., Mihatsch M.J., Gasser T.C., and Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 116 (2001) 79-86
22. Sobin L.H., and Wittekind Ch. International Union against Cancer. TNM classification of malignant tumours. 6th ed. (2002), Wiley, New York
23. Lopez-Beltran A., Sauter G., Gasser T., Hartmann A., Schmitz-Dräger B.J., Helpap B., Ayala A.G., Tamboli P., Knowles M.A., Sidransky D., Cordon-Cardo C., Jones P.A., Cairns P., Simon R., Amin M.B., and Tyczynsky J.E. Tumours of the urinary system. In: Eble J.N., Sauter G., Epstein J.I., and Sesterhenn I.A. (Eds). Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours (2004), IARC Press, Lyon
24. Halling K.C. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 3 (2003) 507-519 [Erratum in: Expert Rev Mol Diagn 2004;4:266]
25. Pycha A., Lodde M., Comploj E., Negri G., Egarter-Vigl E., Vittadello F., Lusuardi L., Palermo S., and Mian C. Intermediate-risk urothelial carcinoma: an unresolved problem?. Urology 63 (2004) 472-475
26. van Rhijn B.W., van der Poel H.G., and van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47 (2005) 736-748
27. Sarosdy M.F., Schellhammer P., Bokinsky G., Kahn P., Chao R., Yore L., Zadra J., Burzon D., Osher G., Bridge J.A., Anderson S., Johansson S.L., Lieber M., Soloway M., and Flom K. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168 (2002) 1950-1954
28. Placer J., Espinet B., Salido M., Sole F., and Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 42 (2002) 547-552
29. Skacel M., Fahmy M., Brainard J.A., Pettay J.D., Biscotti C.V., Liou L.S., Procop G.W., Jones J.S., Ulchaker J., Zippe C.D., and Tubbs R.R. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169 (2003) 2101-2105
30. Laudadio J., Keane T.E., Reeves H.M., Savage S.J., Hoda R.S., Lage J.M., and Wolff D.J. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int 96 (2005) 1280-1285
31. Bittard H., Lamy B., and Billery C. Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer. J Urol 155 (1996) 1887-1891
32. Degtyar P., Neulander E., Zirkin H., Yusim I., Douvdevani A., Mermershtain W., Kaneti J., and Manor E. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Urology 63 (2004) 398-401
33. Steidl C., Simon R., Burger H., Brinkschmidt C., Hertle L., Bocker W., and Terpe H.J. Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. J Pathol 198 (2002) 115-120
34. Theodorescu D. Molecular pathogenesis of urothelial bladder cancer. Histol Histopathol 18 (2003) 259-274
35. Soloway M.S., Sofer M., and Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167 (2002) 1573-1583